Agent Capital

Agent Capital is a venture capital firm based in Waltham, Massachusetts, founded in 2017. The firm specializes in early-to-late stage investments in healthcare-related companies throughout the United States. Its investment focus includes sectors such as immunology, neuroscience, oncology, ophthalmology, and rare diseases. As a Registered Investment Adviser, Agent Capital is dedicated to supporting the growth of innovative healthcare solutions.

Vissaagan Gopalakrishnan

Associate

Preston Noon

Partner, Co-Founder

Bruce Peacock

Venture Partner & Operating Partner

Geeta Vemuri

Managing Partner, Founder

21 past transactions

Carisma Therapeutics

Series C in 2022
Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.

Carbon Biosciences

Series A in 2022
Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities.

Vittoria Biotherapeutics

Seed Round in 2022
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.

Cyrus Biotechnology

Series B in 2021
Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington.

Carisma Therapeutics

Series B in 2021
Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.

Carisma Therapeutics

Series B in 2021
Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.

Metagenomi

Series A in 2020
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.

Palvella Therapeutics

Series C in 2020
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.

Interius BioTherapeutics

Private Equity Round in 2020
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.

ImCheck Therapeutics

Series B in 2019
ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

Metagenomi

Series A in 2019
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.

Pyxis Oncology

Series A in 2019
Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.

Entrada Therapeutics

Series A in 2018
Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.

Verge Genomics

Series A in 2018
Verge Genomics focuses on accelerating drug discovery for neurodegenerative diseases through the use of artificial intelligence and genomic data. The company has developed a platform that leverages machine learning to analyze large datasets, identifying genetic targets and predicting effective therapeutics. By mapping genes associated with various neurodegenerative conditions, Verge aims to discover drugs that can simultaneously target multiple genetic factors. Founded by experts in machine learning and neuroscience, Verge Genomics seeks to improve patient outcomes and reduce the costs associated with pharmaceutical development. The company is based in Mountain View, California, and has formed a strategic alliance with Datavant to enhance its data-driven approach.

Pliant Therapeutics

Series B in 2018
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Carisma Therapeutics

Series A in 2018
Carisma Therapeutics is a biotechnology company focused on developing innovative cellular immunotherapies to treat solid tumors. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating CAR macrophages, which utilize chimeric antigen receptor technology and adoptive cell transfer. This approach aims to enhance cancer treatment by enabling macrophages to infiltrate solid tumor microenvironments, thereby providing robust cellular immunotherapy options for patients. Carisma leverages advancements in macrophage biology and engineering to improve therapeutic outcomes in oncology.

Skyhawk Therapeutics

Venture Round in 2018
Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping.

Orchard Therapeutics

Series B in 2017
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Orbus Therapeutics

Series B in 2017
They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.

Dragonfly Therapeutics

Venture Round in 2017
Dragonfly Therapeutics, Inc. develops drugs to stimulate immune responses against cancer using its platform TriNKET. Dragonfly Therapeutics, Inc. has strategic collaborations with Celgene Corporation and Merck. The company was founded in 2015 and is based in Waltham, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.